Drugs / SAIT301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02296879 | Jan 2015 → Mar 2017 | cancer | Young Suk Park | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAIT301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02296879 ↗ |
| Action | Inhibit | “Binding of SAIT301 to c-MET blocks HGF binding and inhibits HGF-mediated signaling.” NCT02296879 ↗ |
| Route | Intravenous | “SAIT301 will be administered as an intravenous (IV) infusion” NCT02296879 ↗ |